SolasCure
SolasCure is dedicated to transforming chronic wound care through innovative therapeutic solutions. The company is at the forefront of developing Aurase Wound Gel, a breakthrough enzymatic debrider designed to return chronic wounds to healing. SolasCure aims to shift the paradigm in wound care by providing high-impact, safe, and effective treatments that address the underlying causes of wounds rather than just managing symptoms. With a strong focus on research and development, SolasCure is committed to improving the health and wellbeing of patients worldwide.
SolasCure
Wellington House, East Road, Cambridge, Cambridgeshire, CB1 1BH
What We Do
Aurase Wound Gel is a patented biomimetic product designed as a safe and effective debrider for chronic wounds. It contains Tarumase, an enzyme derived from maggot saliva, optimized for wound bed preparation. The gel is suitable for use in all patient settings, offering a simple application during standard dressing changes and is temperature stable for community use.
Application Area
Key People
News & Updates
SolasCure has partnered with the U.S. Army Institute of Surgical Research to evaluate Aurase Wound Gel for treating infected wounds in combat scenarios. The collaboration aims to assess the gel's enzymatic debridement properties in reducing wound biofilm production and bioburden.
This article discusses the potential of enzymes in wound care, highlighting the benefits of Aurase Wound Gel in providing effective, painless debridement and improving healing rates for chronic wounds.
SolasCure was selected for the Innovate UK & TMC Innovation Accelerator Program in partnership with Texas Medical Center in 2024.
In 2024, SolasCure received the Biomedical Catalyst Grant from Innovate UK, the UK's innovation agency.
SolasCure was awarded the EIC Accelerator Grant by the European Innovation Council in 2023.
SolasCure was recognized as a Life Sciences Innovator in 2023 by the UK Department for Business and Trade.